Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs
The DOI matches its Crossref record; 248 of the 249 references it cites were found in a registry or an index.
Abstract
There is a high prevalence of painful diabetic polyneuropathy (pDPN) with around one-third of all patients with diabetes suffering from pDPN. pDPN has debilitating consequences, with a major impact on morbidity and quality of life. Unfortunately, there is no globally licenced pharmacotherapy that modulates the underlying disease mechanisms to prevent or halt the progression of diabetic neuropathy. The cornerstone of treatment therefore remains optimising glycaemic control and cardiovascular risk factors, and symptom control. Evidence from placebo-controlled studies has shown that antidepressants and anticonvulsants are effective for alleviating pDPN. Current clinical guidelines recommend the treatment of pDPN through the use of amitriptyline (tricyclic antidepressant), duloxetine (serotonin norepinephrine reuptake inhibitor), gabapentin and pregabalin (α2-δ ligands), tramadol and tapentadol (μ receptor agonists and norepinephrine reuptake inhibitors) and topical agents such as capsaicin (transient receptor potential V1 receptor desensitizer), although the latter is known to cause degeneration of small nerve fibers. pDPN can be difficult to treat, which frustrates healthcare providers, patients and caregivers. There is an additional need for clinical trials of novel therapeutic agents and optimal combinations for the management of pDPN. This article reviews the pharmacological management of pDPN, emerging therapies, the difficulties of placebo response in clinical trials and n…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [554]
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [554]
In the citing paper
“Electrophysiological testing or referral to a neurologist is rarely needed for diagnosis, except in situations where the clinical features are atypical, the diagnosis is unclear, and a different etiology is suspected.547,554,565”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [554]
In the citing paper
“Moderate improvements in pain are considered to be approximately 30–50% pain relief, whereas a good outcome is considered greater than 50% pain relief [10].”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · cited 1×
“In the Diabetes Control and Complications Trial (DCCT), the prevalence of DPN in the conventional treatment arm was ~ 20%, whilst in the intensive treatment arm it was 10% after 5 years, in those with type 1 diabetes (T1D) who were non-neuropathic at baseline [17].”
BackgroundPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 2×
“3) for amitriptyline in the treatment of neuropathic pain [55, 111].”
BackgroundThe validation of visual analogue scales as ratio scale measures for chronic and experimental pain
Price, D. D., McGrath, P. A., Rafii, A., & Buckingham, B. (1983) · Pain · doi:10.1016/0304-3959(83)90126-4 · Cited by 3,921
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 6×
“ER extended release, NM not mentioned, NR not recommended, NICE National Institute of Clinical Excellence[30], AACE American Association of Clinical Endocrinologists [32], EFNS European Federation of Neurological Societies Task Force [34], AAN American Academy of Neurology [33], ADA American Diabetes Association [31]…”
BackgroundInfluentialClinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain
Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., Donovan, M. I., Fishbain, D. A., Foley, K. M., Fudin, J., et al. (2009) · The Journal of Pain · doi:10.1016/j.jpain.2008.10.008 · Cited by 2,192
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873 · cited 3×
“ER extended release, NM not mentioned, NR not recommended, NICE National Institute of Clinical Excellence[30], AACE American Association of Clinical Endocrinologists [32], EFNS European Federation of Neurological Societies Task Force [34], AAN American Academy of Neurology [33], ADA American Diabetes Association [31]…”
BackgroundBackonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,533
Young, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502 · cited 1×
“5% of the population had DPN, with increasing prevalence related to older age and duration of diabetes [14].”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323 · cited 3×
“Deep burning pain is considered a good discriminator of painful neuropathy as suggested by the EURODIAB study [19].”
BackgroundSelf-citationEffects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy
Max, M. B., Lynch, S. A., Muir, J., Shoaf, S. E., Smoller, B., & Dubner, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205073261904 · Cited by 1,117 · cited 9×
“Co-prescription with serotonergic drugs (e.g. selective serotonin reuptake inhibitors (SSRIs) and TCAs) increases the risk of serotonin syndrome and should be avoided, particularly monoamine oxidase inhibitors or tramadol [123].”
BackgroundInfluentialMorphine, Gabapentin, or Their Combination for Neuropathic Pain
Gilron, I., Bailey, J. M., Tu, D., Holden, R. R., Weaver, D. F., & Houlden, R. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042580 · Cited by 1,091 · cited 1×
“[142] performed a double-blind, randomized, active placebo-controlled, four-period crossover trial to determine the efficacy of gabapentin, morphine or their combination against placebo for the treatment of neuropathic pain (N = 57; 35 pDPN and 22 post-herpetic neuralgia).”
MethodAbbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868 · cited 2×
“There was an increased risk of painful symptoms in patients with T2D, women and people of South Asian origin [7].”
BackgroundAn internet survey of 2,596 people with fibromyalgia
Bennett, R. M., Jones, J., Turk, D. C., Russell, I. J., & Matallana, L. (2007) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-8-27 · Cited by 865 · cited 1×
“in disorders where disturbed sleep is a cardinal feature, such as fibromyalgia [207, 208].”
BackgroundDuloxetine vs. placebo in patients with painful diabetic neuropathy
Goldstein, D. J., Lu, Y., Detke, M. J., Lee, T. C., & Iyengar, S. (2005) · Pain · doi:10.1016/j.pain.2005.03.029 · Cited by 858 · cited 1×
“[124] performed an large placebo-controlled RCT to determine the efficacy of duloxetine in the treatment of pDPN (N = 457).”
MethodAntidepressants for neuropathic pain
Saarto, T., & Wiffen, P. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005454.pub2 · Cited by 764 · cited 2×
“pDPN, there is a lack of data to support its use, with only one small study (N = 12 participants) in pDPN included in a Cochrane review [29].”
BackgroundThe Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes
Davies, M., Brophy, S., Williams, R., & Taylor, A. (2006) · Diabetes Care · doi:10.2337/dc05-2228 · Cited by 746
The Health Care Costs of Diabetic Peripheral Neuropathy in the U.S.
Gordois, A., Scuffham, P., Shearer, A., Oglesby, A., & Tobian, J. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1790 · Cited by 734
Rosenstock, J., Tuchman, M., LaMoreaux, L., & Sharma, U. (2004) · Pain · doi:10.1016/j.pain.2004.05.001 · Cited by 725 · cited 1×
“performed a double-blind RCT of pregabalin 300 mg/day and placebo over a period of 8 weeks (N = 146) [60].”
Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood
Max, M. B., Culnane, M., Schafer, S. C., Gracely, R. H., Walther, D. J., Smoller, B., & Dubner, R. (1987) · Neurology · doi:10.1212/wnl.37.4.589 · Cited by 702
A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11536200-000000000-00000 · Cited by 690 · cited 3×
“more quickly from the gastrointestinal tract and achieves peak blood concentrations 1 h after oral administration [43].”
BackgroundLocal Anesthetics and the Inflammatory Response: A New Therapeutic Indication?
Hollmann, M. W., Durieux, M. E., & Fisher, D. M. (2000) · Anesthesiology · doi:10.1097/00000542-200009000-00038 · Cited by 688
Individual differences in pain: understanding the mosaic that makes pain personal
Fillingim, R. B. (2017) · Pain · doi:10.1097/j.pain.0000000000000775 · Cited by 658 · cited 1×
“The individual variability in pain perception poses additional challenges to assessing and treating pain [246, 247].”
BackgroundBril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634 · cited 5×
“Additionally, gabapentin is given first- or second-line status by all guidelines [33].”
BackgroundInfluentialHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629 · cited 3×
“ER extended release, NM not mentioned, NR not recommended, NICE National Institute of Clinical Excellence[30], AACE American Association of Clinical Endocrinologists [32], EFNS European Federation of Neurological Societies Task Force [34], AAN American Academy of Neurology [33], ADA American Diabetes Association [31]…”
BackgroundAntidepressants in the Treatment of Neuropathic Pain
Sindrup, S. H., Otto, M., Finnerup, N. B., & Jensen, T. S. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_96696601.x · Cited by 624
The SEARCH for Diabetes in Youth Study: Rationale, Findings, and Future Directions
Hamman, R. F., Bell, R. A., Dabelea, D., D’Agostino, R. B., Dolan, L., Imperatore, G., Lawrence, J. M., Linder, B., Marcovina, S. M., Mayer-Davis, E. J., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0574 · Cited by 619 · cited 2×
“In the SEARCH for Diabetes in Youth Study [20], in those of an age of 20 years or less with a duration of diabetes of greater than 5 years, the prevalence was 7% in patients with T1D and 22% in T2D [21].”
BackgroundFreynhagen, R., Strojek, K., Griesing, T., Whalen, E., & Balkenohl, M. (2005) · Pain · doi:10.1016/j.pain.2005.02.032 · Cited by 572
Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial
Lesser, H., Sharma, U., LaMoreaux, L., & Poole, R. M. (2004) · Neurology · doi:10.1212/01.wnl.0000145767.36287.a1 · Cited by 570
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565 · cited 1×
“Overall, duloxetine dosed at 60 mg or greater is effective in treating pDPN, but not at 40 mg or lower doses [134].”
BackgroundOral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy
Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., Munzel, U., Yakhno, N., Raz, I., Novosadova, M., et al. (2006) · Diabetes Care · doi:10.2337/dc06-1216 · Cited by 562
Gabapentin for chronic neuropathic pain in adults
Wiffen, P. J., Derry, S., Bell, R. F., Rice, A. S., Tölle, T. R., Phillips, T., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub4 · Cited by 561 · cited 2×
“A Cochrane review of nine RCTs, including three unpublished studies [54], calculated a number-needed-to-treat for benefit (NNTB) of 5.”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Epidemiology and Impact on Quality of Life of Postherpetic Neuralgia and Painful Diabetic Neuropathy
Schmader, K. E. (2002) · The Clinical Journal of Pain · doi:10.1097/00002508-200211000-00002 · Cited by 550 · cited 1×
“The prevalence of pDPN in the USA is estimated at 20–24% among patients with peripheral neuropathy [23].”
BackgroundDiabetes in Older Adults: A Consensus Report
Sue Kirkman, M., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12035 · Cited by 548 · cited 1×
“In the USA the incidence of diabetes increases with age until about 65 years, after which both incidence and prevalence seem to plateau [199].”
BackgroundInfluence of trial sample size on treatment effect estimates: meta-epidemiological study
Dechartres, A., Trinquart, L., Boutron, I., & Ravaud, P. (2013) · BMJ · doi:10.1136/bmj.f2304 · Cited by 544 · cited 2×
“The vasodilatory response of vessels to nitrates suggests a potential role in pDPN [164].”
BackgroundGabapentin: pharmacology and its use in pain management
Rose, M. A., & Kam, P. C. A. (2002) · Anaesthesia · doi:10.1046/j.0003-2409.2001.02399.x · Cited by 535 · cited 1×
“Compared with other anticonvulsant drugs the α2-δ ligands do not have significant drug interactions, predominantly as a result of their lack of hepatic metabolism or their modulation of cytochrome P450 activity [42].”
BackgroundRaskin, J., Pritchett, Y. L., Wang, F., D'Souza, D. N., Waninger, A. L., Iyengar, S., & Wernicke, J. F. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00061.x · Cited by 532 · cited 1×
“Two further RCTs similarly found duloxetine 60 mg and 120 mg to be superior to placebo for pDPN [125, 126].”
BackgroundGore, M., Brandenburg, N. A., Dukes, E., Hoffman, D. L., Tai, K.-S., & Stacey, B. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2005.04.009 · Cited by 525
Rowbotham, M. C., Goli, V., Kunz, N. R., & Lei, D. (2004) · Pain · doi:10.1016/j.pain.2004.05.010 · Cited by 521 · cited 1×
“A double-blind RCT compared venlafaxine extended-release at 75 mg or 150/225 mg versus placebo for the treatment of pDPN [137].”
BackgroundA randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain
Wernicke, J. F., Pritchett, Y. L., D’Souza, D. N., Waninger, A., Tran, P., Iyengar, S., & Raskin, J. (2006) · Neurology · doi:10.1212/01.wnl.0000240225.04000.1a · Cited by 510
Watson, P. C. N., Moulin, D., Watt-Watson, J., Gordon, A., & Eisenhoffer, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00160-x · Cited by 510 · cited 1×
“Two short-term RCTs of oxycodone have shown efficacy in pDPN (4 weeks/6 weeks) [162, 163]; however, one of these studies had a small sample size (N = 36) and was thus liable to bias.”
BackgroundGilron, I., Bailey, J. M., Tu, D., Holden, R. R., Jackson, A. C., & Houlden, R. L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61081-3 · Cited by 500 · cited 1×
“Further comparator studies have reported the efficacy of a number of different treatment combinations for neuropathic pain, including nortriptyline and gabapentin [143], prolonged-release oxycodone and gabapentin [144], imipramine and pregabalin [118], and nortriptyline and morphine [145].”
BackgroundDiabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487 · cited 4×
“Topical lidocaine and GTN patches may be used in combination to provide 24-h pain cover with alternating 12-h application of each therapy [12, 159].”
BackgroundMethodResultInfluentialSelf-citationRichter, R. W., Portenoy, R., Sharma, U., Lamoreaux, L., Bockbrader, H., & Knapp, L. E. (2005) · The Journal of Pain · doi:10.1016/j.jpain.2004.12.007 · Cited by 473
Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial
Gimbel, J. S., Richards, P., & Portenoy, R. K. (2003) · Neurology · doi:10.1212/01.wnl.0000057720.36503.2c · Cited by 469 · cited 1×
“Two short-term RCTs of oxycodone have shown efficacy in pDPN (4 weeks/6 weeks) [162, 163]; however, one of these studies had a small sample size (N = 36) and was thus liable to bias.”
BackgroundDaousi, C., MacFarlane, I. A., Woodward, A., Nurmikko, T. J., Bundred, P. E., & Benbow, S. J. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01271.x · Cited by 454 · cited 1×
“5% had never reported symptoms to their doctor and 39% had never received treatment for their pain [25].”
BackgroundMorello, C. M., Leckband, S. G., Stoner, C. P., Moorhouse, D. F., & Sahagian, G. A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1931 · Cited by 445 · cited 2×
“Comparator studies have shown gabapentin to have equal [51] or superior efficacy to amitriptyline [52].”
BackgroundMcNicol, E. D., Midbari, A., & Eisenberg, E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006146.pub2 · Cited by 434
Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials
Backonja, M., & Glanzman, R. L. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90011-7 · Cited by 425 · cited 1×
“A dosing regimen with titration up to 1800 mg and maximum upper dose of 3600 mg is recommended in pDPN [45].”
Abuse and Misuse of Pregabalin and Gabapentin
Evoy, K. E., Morrison, M. D., & Saklad, S. R. (2017) · Drugs · doi:10.1007/s40265-017-0700-x · Cited by 410 · cited 2×
“There have been recent concerns regarding the misuse and safety of pregabalin and gabapentin, which has led to its reclassification to a controlled drug in the UK [90, 91].”
BackgroundAlbers, J. W., Herman, W. H., Pop-Busui, R., Feldman, E. L., Martin, C. L., Cleary, P. A., Waberski, B. H., Lachin, J. M., & for the DCCT/EDIC Research Group (2010) · Diabetes Care · doi:10.2337/dc09-1941 · Cited by 401
Ca2+ channel α2δ ligands: novel modulators of neurotransmission
Dooley, D. J., Taylor, C. P., Donevan, S., & Feltner, D. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.12.006 · Cited by 387
Chou, R., Ballantyne, J. C., Fanciullo, G. J., Fine, P. G., & Miaskowski, C. (2009) · The Journal of Pain · doi:10.1016/j.jpain.2008.10.007 · Cited by 383
Painful Diabetic Neuropathy: Epidemiology, Natural History, Early Diagnosis, and Treatment Options
Veves, A., Backonja, M., & Malik, R. A. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00347.x · Cited by 375
Polydefkis, M., Hauer, P., Sheth, S., Sirdofsky, M., Griffin, J. W., & McArthur, J. C. (2004) · Brain · doi:10.1093/brain/awh175 · Cited by 375 · cited 2×
“At present, we do not recommended capsaicin in the treatment of pDPN for this reason [188].”
BackgroundVinik, A. I., Nevoret, M.-L., Casellini, C., & Parson, H. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.001 · Cited by 366
Pregabalin for neuropathic pain in adults
Derry, S., Bell, R. F., Straube, S., Wiffen, P. J., Aldington, D., & Moore, R. A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007076.pub3 · Cited by 364 · cited 5×
“Pregabalin [77, 80] 25–75 mg 2–3 times per day (usual starting dose is 75mg per day/twice daily with subsequent up-titration depending on age and renal function) 150–600 mg in 2–3 divided dosages Dizziness (7–28%) Peripheral oedema (6–16%) Somnolence (6–25%) Weight gain (5–9%) Weakness (2–9%) Headache (7%) Dry mouth (…”
BackgroundInfluentialBiochemical pharmacology of the vanilloid receptor TRPV1: An update
Cortright, D. N., & Szallasi, A. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04082.x · Cited by 331 · cited 1×
“The depletion of substance P and desensitisation of TRPV1 causes a reduction of painful stimuli [183, 184].”
BackgroundLauria-Horner, B. A., & Pohl, R. B. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.663 · Cited by 327 · cited 1×
“However, it is more potent and displays a superior preferable pharmacokinetic properties [43, 58].”
BackgroundFreeman, R., Durso-DeCruz, E., & Emir, B. (2008) · Diabetes Care · doi:10.2337/dc07-2105 · Cited by 322 · cited 1×
“Higher doses are associated with more adverse events but doses of ≤ 150 mg are unlikely to be effective [77, 81].”
BackgroundTesfaye, S., Wilhelm, S., Lledo, A., Schacht, A., Tölle, T., Bouhassira, D., Cruccu, G., Skljarevski, V., & Freynhagen, R. (2013) · Pain · doi:10.1016/j.pain.2013.05.043 · Cited by 311 · cited 12×
“Small placebo-controlled RCTs have found amitriptyline to be superior to placebo; however, in two of these studies the dose used was over the recommended prescribing doses in current clinical practice (> 100 mg/day) [74, 103–105].”
BackgroundInfluentialSelf-citationCombination pharmacotherapy for the treatment of neuropathic pain in adults
Chaparro, L. E., Wiffen, P. J., Moore, R. A., & Gilron, I. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008943.pub2 · Cited by 310
Macrophage and lymphocyte invasion of dorsal root ganglia after peripheral nerve lesions in the rat
Hu, P., & McLachlan, E. M. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00065-9 · Cited by 310 · cited 1×
“It is postulated that lidocaine modifies sodium channel expression at the DRG reducing peripheral nociceptive sensitisation [195] and may also have anti-inflammatory mechanisms modulating inflammatory cytokines [196], which are thought to have a role in hyperalgesia and central sensitisation [197].”
BackgroundA Review of the Evidence for the Efficacy and Safety of Trazodone in Insomnia
Mendelson, W. B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0409 · Cited by 308 · cited 1×
“in disorders where disturbed sleep is a cardinal feature, such as fibromyalgia [207, 208].”
BackgroundAntiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews
Wiffen, P. J., Derry, S., Moore, R. A., Aldington, D., Cole, P., Rice, A. S., Lunn, M. P., Hamunen, K., Haanpaa, M., & Kalso, E. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010567.pub2 · Cited by 306 · cited 1×
“Current neuropathic pain therapies have accompanying side effects (nausea, sedation, dizziness, dry mouth, weight gain, falls) that occur in 40% of people and are dose dependent [248].”
BackgroundJaiswal, M., Divers, J., Dabelea, D., Isom, S., Bell, R. A., Martin, C. L., Pettitt, D. J., Saydah, S., Pihoker, C., Standiford, D. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0179 · Cited by 303 · cited 4×
“There was an increased risk of painful symptoms in patients with T2D, women and people of South Asian origin [7].”
BackgroundInfluentialEfficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial
Max, M. B., Kishore-Kumar, R., Schafer, S. C., Meister, B., Gracely, R. H., Smoller, B., & Dubner, R. (1991) · Pain · doi:10.1016/0304-3959(91)90157-s · Cited by 301
Treatment of Painful Diabetic Neuropathy With Topical Capsaicin
(1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.11.2225 · Cited by 291
Amitriptyline for neuropathic pain in adults
Moore, R. A., Derry, S., Aldington, D., Cole, P., & Wiffen, P. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008242.pub3 · Cited by 286 · cited 4×
“3) for amitriptyline in the treatment of neuropathic pain [55, 111].”
BackgroundInfluentialDworkin, R. H., Turk, D. C., Peirce-Sandner, S., Burke, L. B., Farrar, J. T., Gilron, I., Jensen, M. P., Katz, N. P., Raja, S. N., Rappaport, B. A., et al. (2012) · Pain · doi:10.1016/j.pain.2012.03.003 · Cited by 285 · cited 1×
“A high placebo effect has been previously shown in trials of analgesics [235] and thus may mask the positive treatment effect in neuropathic pain trials [236].”
BackgroundSevere chronic pain is associated with increased 10 year mortality. A cohort record linkage study
Torrance, N., Elliott, A. M., Lee, A. J., & Smith, B. H. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2009.07.006 · Cited by 276 · cited 1×
“Unfortunately, there are data to suggest that mortality is higher in patients with severe chronic pain [24].”
BackgroundCyclic antidepressants and the risk of sudden cardiac death
Ray, W. A., Meredith, S., Thapa, P. B., Hall, K., & Murray, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.019 · Cited by 274 · cited 1×
“There are data to suggest that TCAs were associated with increased relative risk and higher doses (amitriptyline 100 mg equivalent) should be used cautiously, particularly in patients with an elevated baseline risk of sudden death [201].”
BackgroundSchwartz, S., Etropolski, M., Shapiro, D. Y., Okamoto, A., Lange, R., Haeussler, J., & Rauschkolb, C. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.537589 · Cited by 262 · cited 2×
“A pooled analysis of 396 patients with pDPN demonstrated a 30% pain reduction in 65% of patients and a 50% pain reduction in ~ 35% of patients [156].”
BackgroundMethodImipramine Treatment of Painful Diabetic Neuropathy
Kvinesdal, B. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340370059031 · Cited by 258
Mechanisms of analgesia by gabapentin and pregabalin – Calcium channel α2-δ [Cavα2-δ] ligands
Taylor, C. P. (2009) · Pain · doi:10.1016/j.pain.2008.11.019 · Cited by 257 · cited 5×
“Gabapentin and pregabalin are γ-aminobutyric acid (GABA) mimetics; however, they do not bind to the GABA receptor, but exert their analgesic effect through high affinity binding and modulation of the calcium channel α2-δ proteins in the dorsal root ganglion (DRG) [40].”
BackgroundInfluentialMisuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?
Schifano, F. (2014) · CNS Drugs · doi:10.1007/s40263-014-0164-4 · Cited by 250 · cited 1×
“At therapeutic doses, pregabalin and gabapentin have a low risk of addiction [93].”
BackgroundBurden of Illness in Painful Diabetic Peripheral Neuropathy: The Patients’ Perspectives
Gore, M., Brandenburg, N. A., Hoffman, D. L., Tai, K.-S., & Stacey, B. (2006) · The Journal of Pain · doi:10.1016/j.jpain.2006.04.013 · Cited by 239
Duloxetine: Clinical Pharmacokinetics and Drug Interactions
Knadler, M. P., Lobo, E., Chappell, J., & Bergstrom, R. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539240-000000000-00000 · Cited by 237 · cited 3×
“selective serotonin reuptake inhibitors (SSRIs) and TCAs) increases the risk of serotonin syndrome and should be avoided, particularly monoamine oxidase inhibitors or tramadol [123].”
BackgroundSerotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
Marks, D., Shah, M., Patkar, A., Masand, P., Park, G.-Y., & Pae, C.-U. (2009) · Current Neuropharmacology · doi:10.2174/157015909790031201 · Cited by 236
Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Oates, P. (2008) · Current Drug Targets · doi:10.2174/138945008783431781 · Cited by 231 · cited 1×
“Aldose reductase inhibitors have been successful in reversing experimental diabetic neuropathy [35], although this has not been translated to human clinical trials [36].”
Background(1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400110079017 · Cited by 227
Hanna, M., O'Brien, C., & Wilson, M. C. (2008) · European Journal of Pain · doi:10.1016/j.ejpain.2007.12.010 · Cited by 225 · cited 1×
“Further comparator studies have reported the efficacy of a number of different treatment combinations for neuropathic pain, including nortriptyline and gabapentin [143], prolonged-release oxycodone and gabapentin [144], imipramine and pregabalin [118], and nortriptyline and morphine [145].”
BackgroundBoyle, J., Eriksson, M. E. V., Gribble, L., Gouni, R., Johnsen, S., Coppini, D. V., & Kerr, D. (2012) · Diabetes Care · doi:10.2337/dc12-0656 · Cited by 225 · cited 3×
“However, other studies have found duloxetine to have similar or inferior efficacy to pregabalin and/or gabapentin [56, 74, 131, 132].”
BackgroundQuilici, S., Chancellor, J., Löthgren, M., Simon, D., Said, G., Le, T. K., Garcia-Cebrian, A., & Monz, B. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-6 · Cited by 223 · cited 1×
“However, other studies have found duloxetine to have similar or inferior efficacy to pregabalin and/or gabapentin [56, 74, 131, 132].”
BackgroundPirart, J. (1977) · PubMed · Cited by 220
Tölle, T., Freynhagen, R., Versavel, M., Trostmann, U., & Young, J. P. (2008) · European Journal of Pain · doi:10.1016/j.ejpain.2007.05.003 · Cited by 219
Peltier, A., Goutman, S. A., & Callaghan, B. C. (2014) · BMJ · doi:10.1136/bmj.g1799 · Cited by 218
Zaccara, G., Gangemi, P., Perucca, P., & Specchio, L. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02966.x · Cited by 216 · cited 1×
“The most common adverse events related to pregabalin are similar to those of gabapentin, including: dizziness, somnolence, euphoria, peripheral edema and weight gain [77, 87, 88].”
BackgroundAbstract #100: Acth-Secreting Pheochromocytoma
Kalia-Reynolds, M., Giordano, J., Kalia-Reynolds, I., & Houston, C. (2015) · Endocrine Practice · doi:10.1016/s1530-891x(20)42300-6 · Cited by 208
GORSON, K. C., SCHOTT, C., HERMAN, R., ROPPER, A. H., & RAND, W. M. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.251 · Cited by 206 · cited 1×
“Further smaller studies have found gabapentin to be more effective than placebo at maximum doses of 1200 mg [48] and 3600 mg [49], but not 900 mg/day [50].”
BackgroundRice, A. S. C., Dworkin, R. H., McCarthy, T. D., Anand, P., Bountra, C., McCloud, P. I., Hill, J., Cutter, G., Kitson, G., Desem, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62337-5 · Cited by 204 · cited 1×
“In the first phase 2, double-blind RCT, using a novel study design, EMA401 100 mg twice daily provided superior relief of postherpetic neuralgia compared with placebo [212].”
MethodAmitriptyline: A Review of its Pharmacological Properties and Therapeutic Use in Chronic Pain States
Bryson, H. M., & Wilde, M. I. (1996) · Drugs & Aging · doi:10.2165/00002512-199608060-00008 · Cited by 204
Gabapentin in the treatment of neuropathic pain
Bennett, M. I., & Simpson, K. H. (2004) · Palliative Medicine · doi:10.1191/0269216304pm845ra · Cited by 201 · cited 1×
“Its half-life is 6–8 h, consequently the drug is typically administered three times daily [44].”
BackgroundNiesters, M., Proto, P. L., Aarts, L., Sarton, E. Y., Drewes, A. M., & Dahan, A. (2014) · British Journal of Anaesthesia · doi:10.1093/bja/aeu056 · Cited by 201
Tölle, T., Xu, X., & Sadosky, A. B. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.09.007 · Cited by 199
Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain
Toth, C. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613505614 · Cited by 198 · cited 1×
“Alternative anti-neuropathic agents with theoretical superior cardiovascular safety profile should instead be considered, for example duloxetine and pregabalin [202, 203].”
BackgroundBarbano, R. L., Herrmann, D. N., Hart-Gouleau, S., Pennella-Vaughan, J., Lodewick, P. A., & Dworkin, R. H. (2004) · Archives of Neurology · doi:10.1001/archneur.61.6.914 · Cited by 193 · cited 2×
“Typically, a 5% lidocaine plasters (up to four) may be applied for up to 18 h and is effective in providing analgesia in pDPN [177].”
BackgroundMethodTramadol for neuropathic pain in adults
Duehmke, R. M., Derry, S., Wiffen, P. J., Bell, R. F., Aldington, D., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003726.pub4 · Cited by 191
Arezzo, J. C., Rosenstock, J., LaMoreaux, L., & Pauer, L. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-33 · Cited by 190
Selvarajah, D., Gandhi, R., Emery, C. J., & Tesfaye, S. (2010) · Diabetes Care · doi:10.2337/dc09-1029 · Cited by 189
Self-citationBaron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I., & Serpell, M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903047880 · Cited by 189 · cited 1×
“8) and stabilises the neuronal membrane potential on hyperexcitable small nerve fibers, with a subsequent reduction of ectopic neuronal discharges [75, 176].”
BackgroundThe Topiramate Diabetic Neuropathic Pain Study Group*, Thienel, U., Neto, W., Schwabe, S. K., & Vijapurkar, U. (2004) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2004.00338.x · Cited by 187
Gabapentin and Venlafaxine for the Treatment of Painful Diabetic Neuropathy
Simpson, D. A. (2001) · Journal of Clinical Neuromuscular Disease · doi:10.1097/00131402-200112000-00002 · Cited by 182 · cited 2×
“Further smaller studies have found gabapentin to be more effective than placebo at maximum doses of 1200 mg [48] and 3600 mg [49], but not 900 mg/day [50].”
BackgroundGriebeler, M. L., Morey-Vargas, O. L., Brito, J. P., Tsapas, A., Wang, Z., Carranza Leon, B. G., Phung, O. J., Montori, V. M., & Murad, M. H. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0511 · Cited by 178 · cited 3×
“Duloxetine 60 mg has been shown to be superior to pregabalin 300 mg in two RCTs [76, 130] and pooled analysis [110].”
BackgroundAldose reductase inhibitors for the treatment of diabetic polyneuropathy
Chalk, C., Benstead, T. J., & Moore, F. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004572.pub2 · Cited by 176 · cited 3×
“Aldose reductase inhibitors have been successful in reversing experimental diabetic neuropathy [35], although this has not been translated to human clinical trials [36].”
BackgroundSleep Impairment in Patients With Painful Diabetic Peripheral Neuropathy
Zelman, D. C., Brandenburg, N. A., & Gore, M. (2006) · The Clinical Journal of Pain · doi:10.1097/01.ajp.0000210910.49923.09 · Cited by 176
Clinical trial outcome in neuropathic pain: Relationship to study characteristics
Katz, J., Finnerup, N. B., & Dworkin, R. H. (2008) · Neurology · doi:10.1212/01.wnl.0000275528.01263.6c · Cited by 169
Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy
Campbell, C. M., Kipnes, M. S., Stouch, B. C., Brady, K. L., Kelly, M., Schmidt, W. K., Petersen, K. L., Rowbotham, M. C., & Campbell, J. N. (2012) · Pain · doi:10.1016/j.pain.2012.04.014 · Cited by 165 · cited 2×
“Paroxysmal pain was found to have a better response to pregabalin [118], the preservation of thermal sensation or nociception anticipated a positive response to the topical treatment of pain [191, 254].”
BackgroundVinik, A. I., Tuchman, M., Safirstein, B., Corder, C., Kirby, L., Wilks, K., Quessy, S., Blum, D., Grainger, J., White, J., et al. (2007) · Pain · doi:10.1016/j.pain.2006.09.040 · Cited by 163
The role of sodium channels in neuropathic pain
Rogers, M., Tang, L., Madge, D. J., & Stevens, E. B. (2006) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2006.10.009 · Cited by 163 · cited 1×
“It is postulated that lidocaine modifies sodium channel expression at the DRG reducing peripheral nociceptive sensitisation [195] and may also have anti-inflammatory mechanisms modulating inflammatory cytokines [196], which are thought to have a role in hyperalgesia and central sensitisation [197].”
BackgroundHan, T., Bai, J., Liu, W., & Hu, Y. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0555 · Cited by 160
Vitamin D as an Analgesic for Patients With Type 2 Diabetes and Neuropathic Pain
Lee, P. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.7.771 · Cited by 157
Satoh, J., Yagihashi, S., Baba, M., Suzuki, M., Arakawa, A., Yoshiyama, T., & Shoji, S. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03152.x · Cited by 152
Painful diabetic neuropathy: treatment and future aspects
Ziegler, D. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.817 · Cited by 151 · cited 1×
“The reported prevalence has varied from 8 to 26%, depending on the diagnostic criteria and population studied [5, 22].”
BackgroundTreatment of Chronic Painful Diabetic Neuropathy With Isosorbide Dinitrate Spray
Yuen, K. C. J., Baker, N. R., & Rayman, G. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1699 · Cited by 150 · cited 1×
“in a double-blind crossover trial recruiting 22 patients showed a reduction in pain and pain intensity utilising a locally/topically administered isosorbide dinitrate spray [181].”
MethodLee, C. C., Perkins, B. A., Kayaniyil, S., Harris, S. B., Retnakaran, R., Gerstein, H. C., Zinman, B., & Hanley, A. J. (2015) · Diabetes Care · doi:10.2337/dc14-2585 · Cited by 148 · cited 1×
“50% in patients who developed diabetes, 49% in those with pre-diabetes and 29% in controls [16].”
BackgroundCardiovascular considerations in antidepressant therapy: an evidence-based review.
Yekehtaz, H., Farokhnia, M., & Akhondzadeh, S. (2013) · PubMed Central · Cited by 148
Antiepileptic drugs for neuropathic pain and fibromyalgia
Wiffen, P. J., Derry, S., Moore, R. A., Aldington, D., Cole, P., Rice, A. S. C., Lunn, M. P., Hamunen, K., & Kalso, E. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010567 · Cited by 146
Lynch, M. E., Clark, A. J., Sawynok, J., & Sullivan, M. J. L. (2005) · Anesthesiology · doi:10.1097/00000542-200507000-00021 · Cited by 144
Brines, M., Dunne, A. N., van Velzen, M., Proto, P. L., Ostenson, C.-G., Kirk, R. I., Petropoulos, I. N., Javed, S., Malik, R. A., Cerami, A., et al. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00215 · Cited by 144 · cited 5×
“Additionally, participants with small nerve fiber deficits showed improvements in corneal nerve fiber density, with no change in the placebo group [215].”
BackgroundInfluentialBaba, M., Matsui, N., Kuroha, M., Wasaki, Y., & Ohwada, S. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13013 · Cited by 144 · cited 1×
“A recent large phase 3 RCT (N = 834) found mirogabalin 30 mg per day to be superior to placebo [97].”
BackgroundDiabetic Painful Neuropathy: Current and Future Treatment Options
Chong, M. S., & Hester, J. (2007) · Drugs · doi:10.2165/00003495-200767040-00006 · Cited by 141
Tanenberg, R. J., Irving, G. A., Risser, R. C., AHL, J. S. B., Robinson, M. J., Skljarevski, V., & Malcolm, S. K. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0681 · Cited by 140
Sindrup, S., Gram, L., Skjold, T., Grodum, E., Brosen, K., & Beck‐Nielsen, H. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03836.x · Cited by 138
Prospective Associations of Vitamin D With β-Cell Function and Glycemia
Kayaniyil, S., Retnakaran, R., Harris, S. B., Vieth, R., Knight, J. A., Gerstein, H. C., Perkins, B. A., Zinman, B., & Hanley, A. J. (2011) · Diabetes · doi:10.2337/db11-0465 · Cited by 138
Vitamin D for the treatment of painful diabetic neuropathy
Basit, A., Basit, K. A., Fawwad, A., Shaheen, F., Fatima, N., Petropoulos, I. N., Alam, U., & Malik, R. A. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000148 · Cited by 138
Self-citationDiabetic Neuropathy in Older Adults
Vinik, A. I., Strotmeyer, E. S., Nakave, A. A., & Patel, C. V. (2008) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2008.03.011 · Cited by 137 · cited 1×
“effects on stability, sensorimotor function, gait and activities of daily living [200].”
BackgroundKurien, T., Arendt-Nielsen, L., Petersen, K. K., Graven-Nielsen, T., & Scammell, B. E. (2018) · The Journal of Pain · doi:10.1016/j.jpain.2018.05.011 · Cited by 137 · cited 1×
“The μ opioid agonism interrupts synaptic transmissions of ascending pain signals at the level of the spinal cord and activates descending inhibition supraspinally, while norepinephrine and serotonin re-uptake increases descending inhibitory tone [152].”
BackgroundVrethem, M., Boivie, J., Arnqvist, H., Holmgren, H., Lindström, T., & Thorell, L.-H. (1997) · The Clinical Journal of Pain · doi:10.1097/00002508-199712000-00009 · Cited by 136 · cited 10×
“Co-prescription with serotonergic drugs (e.g. selective serotonin reuptake inhibitors (SSRIs) and TCAs) increases the risk of serotonin syndrome and should be avoided, particularly monoamine oxidase inhibitors or tramadol [123].”
BackgroundInfluentialTreatment of Neuropathic Pain with Venlafaxine: A Systematic Review
Aiyer, R., Barkin, R. L., & Bhatia, A. (2016) · Pain Medicine · doi:10.1093/pm/pnw261 · Cited by 135
Soderstrom, L. H., Johnson, S. P., Diaz, V. A., & Mainous, A. G. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03379.x · Cited by 133 · cited 1×
“82 million) showed a clear association between vitD insufficiency (< 75 nmol/l) and pDPN [226].”
BackgroundVinik, A. I., Shapiro, D. Y., Rauschkolb, C., Lange, B., Karcher, K., Pennett, D., & Etropolski, M. S. (2014) · Diabetes Care · doi:10.2337/dc13-2291 · Cited by 132 · cited 1×
“In 2012, the FDA approved the use of tapentadol ER for the treatment of neuropathic pain [153].”
BackgroundBouhassira, D., Wilhelm, S., Schacht, A., Perrot, S., Kosek, E., Cruccu, G., Freynhagen, R., Tesfaye, S., Lledó, A., Choy, E., et al. (2014) · Pain · doi:10.1016/j.pain.2014.08.020 · Cited by 132 · cited 2×
“In a secondary analysis of the COMBO-DN study, treatment effect showed a trend for high-dose monotherapy in severe pain, whereas combination therapy favoured moderate-mild pain [253].”
BackgroundSelf-citationGabapentin vs. Amitriptyline in Painful Diabetic Neuropathy
Dallocchio, C., Buffa, C., Mazzarello, P., & Chiroli, S. (2000) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00181-0 · Cited by 131 · cited 1×
“Comparator studies have shown gabapentin to have equal [51] or superior efficacy to amitriptyline [52].”
BackgroundVenlafaxine for neuropathic pain in adults
Gallagher, H. C., Gallagher, R. M., Butler, M., Buggy, D. J., & Henman, M. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011091.pub2 · Cited by 130
Häuser, W., Bartram-Wunn, E., Bartram, C., Reinecke, H., & Tölle, T. (2011) · Pain · doi:10.1016/j.pain.2011.01.050 · Cited by 128
Snedecor, S. J., Sudharshan, L., Cappelleri, J. C., Sadosky, A., Mehta, S., & Botteman, M. (2014) · Pain Practice · doi:10.1111/papr.12054 · Cited by 127 · cited 2×
“Another systematic review and meta-analysis has also reported similar efficacy with pregabalin to the 5% lidocaine patch [83].”
BackgroundBansal, D., Bhansali, A., Hota, D., Chakrabarti, A., & Dutta, P. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02806.x · Cited by 127 · cited 2×
“Small comparator studies have shown amitriptyline to be equally efficacious to α2-δ ligands [51, 73, 74, 106], other TCAs [103, 105], topical capsaicin [107], lamotrigine [108] and duloxetine [74, 109].”
BackgroundSodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study
Kochar, D. K., Rawat, N., Agrawal, R. P., Vyas, A., Beniwal, R., Kochar, S. K., & Garg, P. (2004) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hch007 · Cited by 127 · cited 1×
“Two studies in pDPN of sodium valproate showed some benefit in pain relief [171, 172].”
BackgroundOxycodone for neuropathic pain in adults
Gaskell, H., Derry, S., Stannard, C., & Moore, R. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010692.pub3 · Cited by 127
Frampton, J. E., & Scott, L. J. (2004) · Drugs · doi:10.2165/00003495-200464240-00006 · Cited by 126 · cited 2×
“The average half-life is 6 h and it is therefore normally administered in two or three divided doses [43, 57].”
BackgroundDuloxetine versus Routine Care in the Long-Term Management of Diabetic Peripheral Neuropathic Pain
Raskin, J., Smith, T. R., Wong, K., Pritchett, Y. L., D'souza, D. N., Iyengar, S., & Wernicke, J. F. (2006) · Journal of Palliative Medicine · doi:10.1089/jpm.2006.9.29 · Cited by 119
A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy
Segerdahl, A. R., Themistocleous, A. C., Fido, D., Bennett, D. L., & Tracey, I. (2018) · Brain · doi:10.1093/brain/awx337 · Cited by 119 · cited 1×
“Recently, a well-phenotyped fMRI study found that ventrolateral periaqueductal grey functional connectivity is altered in patients suffering from pDPN, which correlates with spontaneous and allodynic pain [251].”
BackgroundVinik, A. I., Perrot, S., Vinik, E. J., Pazdera, L., Jacobs, H., Stoker, M., Long, S., Snijder, R. J., van der Stoep, M., Ortega, E., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0752-7 · Cited by 119 · cited 2×
“There are again limited data on the 8% capsaicin patch, with only one further 52-week study published to date reporting no negative functional or neurological effects compared to standard of care [190].”
BackgroundBiesbroeck, R., Bril, V., Hollander, P. A., Kabadi, U. M., Schwartz, S., Singh, S. P., Wk, W., & Bernstein, J. E. (1995) · PubMed · Cited by 118
Dworkin, R. H., Katz, J., & Gitlin, M. J. (2005) · Neurology · doi:10.1212/wnl.65.12_suppl_4.s7 · Cited by 117 · cited 1×
“Clinical trial design for neuropathic pain agents has received some consideration in view of the issues pertaining to the placebo response [243].”
BackgroundSTRESS AND TRAUMA: Psychotherapy and Pharmacotherapy for Depersonalization/Derealization Disorder.
Gentile, J. P., Snyder, M., & Gillig, P. M. (2014) · Europe PMC (PubMed Central) · Cited by 114
Lamotrigine for chronic neuropathic pain and fibromyalgia in adults
Wiffen, P. J., Derry, S., & Moore, A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006044.pub4 · Cited by 113 · cited 1×
“As discussed earlier, lamotrigine does not have a significant place in neuropathic pain therapy [238] due to limited evidence regarding efficacy.”
BackgroundChio, C. (2003) · Cellular Signalling · doi:10.1016/j.cellsig.2003.10.003 · Cited by 113 · cited 1×
“AT2R activation is thought to increase kinase levels in DRG neurons such as levels of protein kinase A (PKA), protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) [211], and olodanrigan antagonises this effect.”
BackgroundValensi, P. E., Devehat, C. L., Richard, J.-L., Farez, C., Khodabandehlou, T., Rosenbloom, R. A., & LeFante, C. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.05.011 · Cited by 111
Silver, M. T., Blum, D., Grainger, J., Hammer, A. E., & Quessy, S. N. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.12.015 · Cited by 109
A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy
Kaur, H., Hota, D., Bhansali, A., Dutta, P., Bansal, D., & Chakrabarti, A. (2011) · Diabetes Care · doi:10.2337/dc10-1793 · Cited by 109 · cited 2×
“Small comparator studies have shown amitriptyline to be equally efficacious to α2-δ ligands [51, 73, 74, 106], other TCAs [103, 105], topical capsaicin [107], lamotrigine [108] and duloxetine [74, 109].”
BackgroundCulver, D. A., Dahan, A., Bajorunas, D., Jeziorska, M., van Velzen, M., Aarts, L. P. H. J., Tavee, J., Tannemaat, M. R., Dunne, A. N., Kirk, R. I., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-21291 · Cited by 104 · cited 1×
“study of cibinetide also confirmed improvements of small nerve fibers with improvements in pain in sarcoidosis [216].”
ResultA retrospective pooled analysis of duloxetine safety in 23 983 subjects
Gahimer, J., Wernicke, J., Yalcin, I., Ossanna, M. J., Wulster-Radcliffe, M., & Viktrup, L. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162719 · Cited by 102 · cited 1×
“Most adverse events occur early after the onset of treatment, are mild to moderate, and do not worsen with time [136].”
BackgroundReduced vitamin D levels in painful diabetic peripheral neuropathy
SHILLO, P. R., Selvarajah, D., Greig, M., Gandhi, R. A., Rao, G., Wilkinson, I. D., Anand, P., & Tesfaye, S. H. (2018) · Diabetic Medicine · doi:10.1111/dme.13798 · Cited by 102 · cited 2×
“Lower vitD levels are known to correlate with greater severity of neuropathic pain, and measures of nerve dysfunction [225].”
BackgroundSelf-citationPlacebo response in neuropathic pain trials ☆
Quessy, S. N., & Rowbotham, M. C. (2008) · Pain · doi:10.1016/j.pain.2008.06.024 · Cited by 101 · cited 2×
“A placebo run-in period, discontinuation of prior analgesic treatments, flexible dosing rather than fixed-dose assignments, exclusion of subjects with mild pain at baseline and specificity of the pain score instrument have all been considered as putative approaches in minimising the placebo effect to tease out the tru…”
BackgroundMethodCombination of morphine with nortriptyline for neuropathic pain
Gilron, I., Tu, D., Holden, R. R., Jackson, A. C., & Dumerton-Shore, D. (2015) · Pain · doi:10.1097/j.pain.0000000000000149 · Cited by 101 · cited 1×
“Further comparator studies have reported the efficacy of a number of different treatment combinations for neuropathic pain, including nortriptyline and gabapentin [143], prolonged-release oxycodone and gabapentin [144], imipramine and pregabalin [118], and nortriptyline and morphine [145].”
BackgroundAnand, U., Facer, P., Yiangou, Y., Sinisi, M., Fox, M., McCarthy, T., Bountra, C., Korchev, Y. E., & Anand, P. (2013) · European Journal of Pain · doi:10.1002/j.1532-2149.2012.00269.x · Cited by 100 · cited 1×
“[210] found that AT2R expression was localised in small/medium‐sized cultured neurons of human and rat DRG.”
BackgroundVinik, A., Rosenstock, J., Sharma, U., Feins, K., Hsu, C., & Merante, D. (2014) · Diabetes Care · doi:10.2337/dc14-1044 · Cited by 100 · cited 1×
“phase 2 RCT of mirogabalin at doses of 15 mg, 20 mg and 30 mg per day found it to be superior to placebo in reducing mean daily pain scores [98].”
BackgroundZiegler, D., Duan, W. R., An, G., Thomas, J. W., & Nothaft, W. (2015) · Pain · doi:10.1097/j.pain.0000000000000263 · Cited by 99
Shehab, D., Al-Jarallah, K. F., Abdella, N., Mojiminiyi, O. A., & Mohamedy, H. A. (2015) · Medical Principles and Practice · doi:10.1159/000375304 · Cited by 99 · cited 1×
“A short-term (8 weeks) non-randomized but placebocontrolled trial (N = 112) of oral vitD3 resulted in a reduction in the neuropathic symptom score (NSS), but with no changes were observed in clinical signs or neurophysiological assessments [221].”
BackgroundZin, C. S., Nissen, L. M., O'Callaghan, J. P., Duffull, S. B., Smith, M. T., & Moore, B. J. (2009) · Journal of Pain · doi:10.1016/j.jpain.2009.09.003 · Cited by 97
Topical Amitriptyline Versus Lidocaine in the Treatment of Neuropathic Pain
Ho, K.-Y., Huh, B. K., White, W. D., Yeh, C.-C., & Miller, E. J. (2008) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e318156db26 · Cited by 93 · cited 1×
“(ascertained through a burning response to topical capsaicin) [191, 192].”
BackgroundTreatment of intractable painful diabetic neuropathy with intravenous lignocaine
Viola, V., Newnham, H. H., & Simpson, R. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.05.007 · Cited by 90 · cited 2×
“Subsequently, a double-blind RCT in patients with intractable pDPN (N = 15) refractory to traditional neuropathic pain medication [194] showed a significant analgesic effect with an IV lidocaine infusion at doses of 5 mg/kg and 7.”
BackgroundLidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers
Krumova, E. K., Zeller, M., Westermann, A., & Maier, C. (2012) · Pain · doi:10.1016/j.pain.2011.08.020 · Cited by 89 · cited 1×
“8) and stabilises the neuronal membrane potential on hyperexcitable small nerve fibers, with a subsequent reduction of ectopic neuronal discharges [75, 176].”
BackgroundNortriptyline for neuropathic pain in adults
Derry, S., Wiffen, P. J., Aldington, D., & Moore, R. A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011209.pub2 · Cited by 88
Amitriptyline versus placebo for major depressive disorder
Leucht, C., Huhn, M., & Leucht, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009138.pub2 · Cited by 86 · cited 1×
“Common adverse events include: drowsiness, dry mouth, constipation, difficulty urinating, tachycardia, dizziness/postural hypotension, sexual dysfunction and headache [111, 119].”
BackgroundMackey, S., Greely, H. T., & Martucci, K. T. (2019) · PAIN Reports · doi:10.1097/pr9.0000000000000762 · Cited by 84 · cited 2×
“Functional magnetic resonance imaging (fMRI) may provide brain-based biomarkers of pain [245].”
BackgroundHunziker, M., Suehs, B. T., Bettinger, T. L., & Crismon, M. L. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.08.010 · Cited by 82 · cited 2×
“Duloxetine is rapidly absorbed, reaching maximal plasma concentrations approximately 6 h after administration, reaching a steady state in the bloodstream within 3 days [121].”
BackgroundA Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain
Freynhagen, R., Serpell, M., Emir, B., Whalen, E., Parsons, B., Clair, A., & Latymer, M. (2015) · Pain Practice · doi:10.1111/papr.12146 · Cited by 82 · cited 1×
“The most common adverse events related to pregabalin are similar to those of gabapentin, including: dizziness, somnolence, euphoria, peripheral edema and weight gain [77, 87, 88].”
BackgroundČížková, D., Lukáčová, N., Maršala, M., & Mars̆ala, J. (2002) · Brain Research Bulletin · doi:10.1016/s0361-9230(02)00761-x · Cited by 81 · cited 1×
“There are alterations of neuronal NO synthase in DRG cells and spinal cord that contribute to spinal sensory processing and neuronal plasticity in the dorsal horn (spinal cord) that have been detailed in animal models of DPN [180].”
BackgroundAgrawal, R. P., Goswami, J., Jain, S., & Kochar, D. K. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.12.018 · Cited by 80 · cited 1×
“Two studies in pDPN of sodium valproate showed some benefit in pain relief [171, 172].”
BackgroundMirogabalin: First Global Approval
Deeks, E. D. (2019) · Drugs · doi:10.1007/s40265-019-01070-8 · Cited by 80
Ca2+Channel α2-δ Ligands for the Treatment of Neuropathic Pain
Field, M. J., Li, Z., & Schwarz, J. B. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060650z · Cited by 77
Roth, T. G., van Seventer, R., & Murphy, T. K. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.516142 · Cited by 75
Kulkantrakorn, K., Lorsuwansiri, C., & Meesawatsom, P. (2012) · Pain Practice · doi:10.1111/papr.12013 · Cited by 74 · cited 1×
“However, two studies of capsaicin cream have shown only minimal benefits in pain relief [186, 187].”
BackgroundBansal, D. (2013) · Pain Physician · doi:10.36076/ppj.2013/16/e705 · Cited by 73
Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain
Burness, C. B., & McCormack, P. L. (2015) · Drugs · doi:10.1007/s40265-015-0520-9 · Cited by 73 · cited 1×
“A 12-week double-blind trial in patients with pDPN provided modest improvement in both pain and sleep quality compared to placebo [189].”
BackgroundImipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial
Holbech, J. V., Bach, F. W., Finnerup, N. B., Brøsen, K., Jensen, T. S., & Sindrup, S. H. (2015) · Pain · doi:10.1097/j.pain.0000000000000143 · Cited by 72 · cited 2×
“Further comparator studies have reported the efficacy of a number of different treatment combinations for neuropathic pain, including nortriptyline and gabapentin [143], prolonged-release oxycodone and gabapentin [144], imipramine and pregabalin [118], and nortriptyline and morphine [145].”
Background5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review
Wolff, R. F., Bała, M., Westwood, M. E., Kessels, A. G. H., & Kleijnen, J. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.12995 · Cited by 72
A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia
Lawson, K. (2017) · Biomedicines · doi:10.3390/biomedicines5020024 · Cited by 72
Imipramine for neuropathic pain in adults
Hearn, L., Derry, S., Phillips, T., Moore, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010769.pub2 · Cited by 70
Jose, V. M., Bhansali, A., Hota, D., & Pandhi, P. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02093.x · Cited by 66
Profile of Adverse Events with Duloxetine Treatment: A Pooled Analysis of Placebo-Controlled Studies
Brunton, S., Wang, F., Edwards, S. B., Crucitti, A. S., Ossanna, M. J., Walker, D. J., & Robinson, M. J. (2010) · Drug Safety · doi:10.2165/11319200-000000000-00000 · Cited by 64
Ghadiri‐Anari, A., Mozafari, Z., Gholami, S., Khodaei, S.-A., Zarchi, M. A., Sepehri, F., Nadjarzade, A., Rahmanian, M., & Namiranian, N. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.12.014 · Cited by 63
Rauck, R., Makumi, C. W., Schwartz, S., Graff, O., Meno‐Tetang, G., Bell, C. F., Kavanagh, S. T., & McClung, C. L. (2013) · Pain Practice · doi:10.1111/papr.12014 · Cited by 61 · cited 1×
“A large RCT (N = 421) of a gabapentin pro-drug, gabapentin enacarbil, however did not lead to significant reductions in the mean 24-h pain intensity score compared with placebo [53].”
BackgroundON THE ADDICTIVE POWER OF GABAPENTINOIDS: A MINI-REVIEW
Bonnet, U., Richter, E.-L., Isbruch, K., & Scherbaum, N. (2018) · Psychiatria Danubina · doi:10.24869/psyd.2018.142 · Cited by 60 · cited 1×
“However, prescription of these agents should be avoided, or administered with caution, in patients with substance misuse disorders [90, 94].”
BackgroundWernicke, J. F., Wang, F., Pritchett, Y. L., Smith, T. R., Raskin, J., D'Souza, D. N., Iyengar, S., & Chappell, A. S. (2007) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00258.x · Cited by 59
Patient considerations in the use of tapentadol for moderate to severe pain
Vadivelu, N., Huang, Mirante, Jacoby, Hines, R. L., Braveman, & Sinatra, R. S. (2013) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s28829 · Cited by 58
Chou, R., Carson, S., & Chan, B. K. S. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0877-5 · Cited by 57 · cited 1×
“Small comparator studies have shown amitriptyline to be equally efficacious to α2-δ ligands [51, 73, 74, 106], other TCAs [103, 105], topical capsaicin [107], lamotrigine [108] and duloxetine [74, 109].”
BackgroundBell, D. S. H. (2012) · Case Reports in Endocrinology · doi:10.1155/2012/165056 · Cited by 57
Wanigasekera, V., Mezue, M., Andersson, J., Kong, Y., & Tracey, I. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000924 · Cited by 57 · cited 3×
“[252] determined the utility of fMRI with a capsaicin-induced central sensitisation to differentiate anti-neuropathic therapy (gabapentin) from ineffective (ibuprofen) treatment and both from placebo.”
BackgroundInfluentialEfficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment
Trouvin, A., Perrot, S., & Lloret‐Linares, C. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.347 · Cited by 55
Tapentadol extended release in the management of peripheral diabetic neuropathic pain
Vadivelu, N., Maslin, B., Kai, A., Legler, A., Kodumudi, G., & Berger, J. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s32193 · Cited by 54
A gain-of-function sodium channel β 2-subunit mutation in painful diabetic neuropathy
Alsaloum, M., Estación, M., Almomani, R., Gerrits, M. M., Bönhof, G. J., Ziegler, D., Malik, R. A., Ferdousi, M., Lauria, G., Merkies, I. S. J., et al. (2019) · Molecular Pain · doi:10.1177/1744806919849802 · Cited by 54 · cited 2×
“7 channel antagonist currently undergoing phase 3 trials for pDPN and small fiber neuropathy [204].”
BackgroundRaskin, P., Huffman, C., Toth, C., Asmus, M. J., Messig, M., Sanchez, R. J., & Pauer, L. (2014) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31829ea1a1 · Cited by 53
Amitriptyline versus placebo for major depressive disorder
Leucht, C., Huhn, M., & Leucht, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009138 · Cited by 53
Desipramine for neuropathic pain in adults
Hearn, L., Moore, R. A., Derry, S., Wiffen, P. J., & Phillips, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011003.pub2 · Cited by 53
Alam, U., Fawwad, A., Shaheen, F., Tahir, B., Basit, A., & Malik, R. A. (2017) · Journal of Diabetes Research · doi:10.1155/2017/7928083 · Cited by 53 · cited 1×
“VitD is effective in improving the quality of life (QoL) in patients with pDPN, with reduced emotional distress and overall improvements in wellbeing [228].”
BackgroundSelf-citationCalandre, E. P., Morillas-Arques, P., Molina-Barea, R., Rodriguez-Lopez, C. M., & Rico-Villademoros, F. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-95 · Cited by 52 · cited 2×
“The combination of trazadone (50–300 mg/day) plus pregabalin (75–450 mg/day) has previously been trialled in a two-phase, open-label uncontrolled study for 24 weeks in fibromyalgia [206].”
Background
Research works printed but not linked: 7
- IDF. IDF diabetes atlas. 8th Edition ed: Web; 2017.
- Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci. 2014;11(3–4):37–42.
- Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828–49. · DOI · Paper page
- McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013(8). · DOI · Paper page
- Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140(21–22):297–306.
- Basit A, Basit KA, Fawwad A, Shaheen F, Fatima N, Petropoulos IN, et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diabetes Res Care. 2016;4(1):e000148. · DOI
- H.J. M. Placebo and control event rate. In: McQuay H.J., editor. Systematic reviews in pain research: methodology redefined. IASP Press, Seattle; 2008. pp. 51–6.
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Self-citationDiabetic neuropathy: cutting-edge research and future directions
Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02175-1 · Cited by 234
“23 However, their use is limited by anticholinergic side effects, especially in elderly patients and those with cardiovascular disease.”
Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms?
Calcutt, N. A. (2020) · Pain · doi:10.1097/j.pain.0000000000001922 · Cited by 159
“In contrast to degenerative neuropathy, there are a number of therapies approved by regulatory agencies to alleviate pain in diabetes and others that are used off-label.(9,18) However, it is notable that none were developed to target diabetes-specific mechanisms, although efficacy is both unpredictable and restricted…”
BackgroundMethodManagement of diabetic neuropathy
Cernea, S., & Raz, I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154867 · Cited by 115
Metadata
- Authors
- Alam, U., Sloan, G., & Tesfaye, S.
- Affiliations
- University of Liverpool (GB)
- Royal Hallamshire Hospital (GB)
- Corresponding author
- Alam, Uazman
- Venue
- Drugs
- Published
- 2020-02-10
- Volume
- 80
- Issue
- 4
- Pages
- 363-384
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3005601005
- Cited by
- 104
- References
- 249
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 9 · 2023: 13 · 2022: 20 · 2021: 18 · 2020: 17
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- painful diabetic polyneuropathy, neuropathic pain, pharmacotherapy, antidepressants, antiepileptic drugs, amitriptyline, duloxetine, gabapentin, pregabalin, tramadol, tapentadol, capsaicin, topical agents, new drugs, placebo response, treatment response biomarkers
- MeSH terms
- Anticonvulsants, Antidepressive Agents, Diabetic Neuropathies, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.